4,131 Shares in Illumina, Inc. $ILMN Acquired by EP Wealth Advisors LLC

EP Wealth Advisors LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, Holdings Channel reports. The fund acquired 4,131 shares of the life sciences company’s stock, valued at approximately $726,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. BlackRock Inc. acquired a new stake in shares of Illumina in the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd acquired a new position in Illumina during the 2nd quarter valued at about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Illumina during the 2nd quarter valued at about $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in Illumina during the 2nd quarter worth approximately $129,792,000. Finally, Impact Partnership Wealth LLC raised its stake in shares of Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after purchasing an additional 7,780 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group raised their target price on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Barclays increased their price target on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $188.40.

Illumina Stock Up 1.7%

Shares of NASDAQ:ILMN opened at $223.22 on Tuesday. The company has a market capitalization of $33.71 billion, a PE ratio of 41.65, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The business has a fifty day moving average price of $189.13 and a two-hundred day moving average price of $153.14. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $223.97.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 299,336 shares of Illumina stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the sale, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.